Clinical Aspects and Management of Hypercalcemia

Regulation of Calcium Metabolism and Homeostasis

• Biological Importance: Intra- and extracellular calcium concentrations are vital to many cellular functions. Consequently, these concentrations are tightly controlled within the body.

• Normal Reference Ranges: The normal serum calcium concentration ranges between $2.1$ and $2.6\,mmol/L$. Minor deviations from this range may occur depending on specific assay techniques used by laboratories.

• The PTH-1,25 Vitamin D Axis: Calcium homeostasis is primarily regulated by a feedback loop involving the parathyroid glands, parathyroid hormone ($PTH$), and vitamin D.

  • The parathyroid glands monitor changes in calcium concentrations.

  • In response to these changes, the glands either increase or decrease the secretion of $PTH$.

• Calcium-PTH Relationship: The relationship between serum calcium concentrations and $PTH$ levels is the most critical factor for establishing a differential diagnosis in hypercalcemia cases.

Clinical Significance and Risks of Hypercalcemia

• Prevalence: Hypercalcemia is a relatively common clinical finding.

• Underlying Conditions: It frequently serves as the first clinical sign of serious underlying pathologies, including cancer or hematological malignancies.

• Complications of Untreated Hypercalcemia: If left managed, hypercalcemia can result in significant complications, such as:

  • Kidney stones.

  • Pancreatitis.

  • Osteoporosis.

• Life-Threatening Risks: Severe hypercalcemia is life-threatening, particularly when it develops rapidly. Serum calcium levels exceeding $3.5\,mmol/L$ are considered a medical emergency and require immediate clinical action.

Common and Rare Causes of Hypercalcemia

• Primary Drivers: The overwhelming majority of hypercalcemia cases are caused by two conditions:

  • Primary Hyperparathyroidism (PHPT).

  • Malignancy.

• Mechanisms of Malignancy-Induced Hypercalcemia:

  • Bone Resorption: Common in cases of solid or hematological malignancies with bone metastases.

  • Humoral Factors: Production of hormone-like factors, specifically Parathyroid Hormone-related Peptide ($PTHrP$).

• Other Potential Causes:

  • Sarcoidosis: Ectopic production of active vitamin D.

  • Vitamin D Intoxication: Occurs in various clinical settings.

  • Hyperalbuminemia: Causes a rise in total serum calcium levels due to increased protein binding. However, ionized calcium levels remain unchanged.

  • Medications: Lithium and diuretics (such as thiazides).

  • Rare Conditions: Pheochromocytoma, adrenal insufficiency, and acute immobilization.

Protein Binding and Corrected Calcium

• Fractional Distribution: Just over half of extracellular calcium is bound to proteins (primarily albumin) and anions. The remaining portion exists in an ionized form.

• Biological Activity: The ionized form of calcium is solely responsible for biological actions.

• Corrected Calcium: Because total calcium measurements are influenced by protein levels, laboratories typically "correct" the calcium value based on albumin levels to provide a more accurate physiological measurement.

Clinical Presentation: Signs and Symptoms

• Nature of Symptoms: Symptoms of hypercalcemia are often vague, multi-faceted, and difficult to identify immediately.

• Common Manifestations:

  • Gastrointestinal (GI): General GI distress.

  • Musculoskeletal: Muscle weakness.

  • Neuropsychiatric: Alterations in mental state or mood.

  • Cardiovascular: Various cardiovascular signs.

• Acuity and Degree: The severity of symptoms is directly proportional to both the absolute degree of hypercalcemia and the speed (acuity) at which the serum calcium levels increased.

Diagnostic Workup and the Flowchart Approach

• Step 1: Clinical History: A thorough history is the first step and provides essential clues regarding the underlying etiology.

• Step 2: Serum Parathyroid Hormone ($PTH$) Level: This is the definitive major step in the workup.

  • Elevated or High-Normal $PTH$: Indicates $PTH$-dependent hypercalcemia. This usually points to Primary Hyperparathyroidism and virtually excludes malignancy.

  • Low or Suppressed $PTH$: Indicates a $PTH$-independent cause, which is considered a "sinister" finding. Further investigation for malignancy is mandatory.

• Step 3: PTHrP Testing: If $PTH$ is suppressed, ordering a Parathyroid Hormone-related Peptide ($PTHrP$) level is recommended.

  • Elevated $PTHrP$: Points toward Humoral Hypercalcemia of Malignancy (HHM).

  • Normal $PTHrP$: Often associated with metastatic bone disease, Sarcoidosis, or Familial Hypocalciuric Hypercalcemia ($FHH$).

Primary Hyperparathyroidism (PHPT)

• Epidemiology: Affects approximately $1$ in every $1000$ adults. It is most commonly seen in middle-aged women.

• Pathophysiology: Characterized by the autonomous production of $PTH$ by one or more parathyroid glands.

  • Solitary Parathyroid Adenoma: Accounts for $80\%$ of cases. This is a benign condition.

  • Parathyroid Carcinomas: These are exceedingly rare.

• Syndromic Associations: PHPT can be a component of Multiple Endocrine Neoplasia ($MEN$), particularly when diagnosed in younger patients. In these cases, exhaustive further investigations are required.

• Treatment: Surgery is the only definitive cure.

  • Historical Approach: Full neck exploration to locate the adenoma.

  • Modern Approach: Minimally invasive parathyroidectomy, aided by advanced imaging technologies.

Familial Hypocalciuric Hypercalcemia (FHH)

• Definition: Also known as Familial Benign Hypocalciuric Hypercalcemia ($FBHH$). It is not a disease in the traditional sense but rather a genetic change in the body's "calcium set point."

• Genetics: An autosomal dominant trait with high penetrance.

• Clinical Presentation: Patients are typically asymptomatic with mildly elevated serum calcium levels. Calcium and phosphate homeostasis appear normal. $PTH$ levels are usually normal, though they can vary.

• Diagnosis: Determined by measuring fractional calcium excretion ($FE_{Ca}$). In FHH, this value is low (less than $1\%$). Diagnosis is also supported by finding elevated calcium levels in other family members.

• Management: Patients with FHH should be left alone. They do not require treatment or surgery. Parathyroidectomy is ineffective for FHH and will not correct the hypercalcemia. There are typically no long-term sequelae.

Management of Moderate and Severe Hypercalcemia

• First-Line Treatment: The mainstay of treatment is aggressive hydration and forced diuresis.

• Second-Line / Severe Case Options:

  • Intravenous (IV) Bisphosphonates: Used for more severe or resistant cases.

  • Glucocorticoids.

  • Dialysis: Reserved as a last resort.

• Clinical Imperatives:

  • Never ignore an elevated serum calcium level.

  • In severe cases, draw blood for testing but proceed with treatment immediately; do not wait for laboratory results before acting.